financetom
Business
financetom
/
Business
/
Lazard beats third-quarter profit estimates on dealmaking revival
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lazard beats third-quarter profit estimates on dealmaking revival
Oct 23, 2025 4:23 AM

(Reuters) -Lazard ( LAZ ) sailed past estimates for third-quarter profit on Thursday as dealmaking activity picked up pace, mirroring gains at larger Wall Street rivals.

M&A activity has accelerated as companies show stronger-than-expected resilience to tariffs, supported by stock markets trading near record highs. Pent-up demand among corporate clients after years of elevated interest rates has further boosted activity.

"We see an increasingly constructive environment for both of our businesses, with substantial client engagement firmwide," Lazard ( LAZ ) CEO Peter Orszag said in a statement.

Lazard's ( LAZ ) adjusted financial advisory revenue jumped about 14% in the quarter to a record $422 million.

It had advised on several big-name transactions during the quarter, including Ferrero's $3.1 billion acquisition of WK Kellogg Co and Corteva Agriscience on its planned separation into multiple businesses.

Earlier this month, executives from top Wall Street banks including JPMorgan ( JPM ) and Goldman Sachs ( GS ) said the deals pipeline remained strong.

Lazard ( LAZ ) also runs one of Wall Street's largest restructuring advisory practices, which tends to see stronger activity when markets turn volatile or credit conditions tighten.

The bank said its restructuring and liability management practice advised several high-profile clients including Altice France and First Brands.

ASSET MANAGEMENT SHINES

The company's asset management business posted revenue growth of 8% on an adjusted basis to $294 million. Inflows were a record for the third quarter, the bank said.

Assets under management have climbed across the industry as a broad rally in equities pushed indexes toward record highs, lifting portfolio values and investor confidence.

The improved risk appetite has also drawn investors back to other asset classes.

Lazard ( LAZ ) posted assets under management of $265 billion as of September 30, versus $248 billion a year earlier.

Overall adjusted revenue came in at a record $725 million, up 12% from a year earlier.

The investment bank reported an adjusted profit of 56 cents per share. Analysts on average had expected 45 cents per share, according to estimates compiled by LSEG.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Marimaca Copper Secures Option to Buy Madrugador Project in Chile
Marimaca Copper Secures Option to Buy Madrugador Project in Chile
Dec 17, 2024
07:32 AM EST, 12/17/2024 (MT Newswires) -- Marimaca Copper ( MARIF ) said Tuesday that it signed a binding option agreement to acquire the Madrugador project in Chile. The company said Madrugador is located near the Pampa Medina project, and the acquisition consolidated its ownership of the southern extent of the Sierra de Medina property package. Under the terms, Marimaca...
Teva, Sanofi say drug to treat IBD met primary targets
Teva, Sanofi say drug to treat IBD met primary targets
Dec 17, 2024
JERUSALEM, Dec 17 (Reuters) - Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and Crohn's disease showed it had met primary goals. Teva and Sanofi said last year they would collaborate on developing a treatment for inflammatory bowel disease (IBD), hoping it will become a blockbuster drug - or one...
IDEAYA Biosciences Gets Move-Forward Dose for Phase 2/3 Darovasertib-Crizotinib Trial
IDEAYA Biosciences Gets Move-Forward Dose for Phase 2/3 Darovasertib-Crizotinib Trial
Dec 17, 2024
07:30 AM EST, 12/17/2024 (MT Newswires) -- IDEAYA Biosciences ( IDYA ) said Tuesday an independent data monitoring committee has recommended a move-forward dose for a potential registration-enabling phase 2/3 trial to evaluate the company's darovasertib combined with Pfizer's ( PFE ) crizotinib in patients with a certain metastatic uveal melanoma. Chief Medical Officer Darrin Beaupre said the committee's recommendation...
Talos Energy to terminate poison pill after agreement with Carlos Slim's firm
Talos Energy to terminate poison pill after agreement with Carlos Slim's firm
Dec 17, 2024
Dec 17 (Reuters) - Talos Energy ( TALO ) said on Tuesday it would terminate its so-called poison pill after it reached an agreement with Mexican billionaire Carlos Slim's investment firm that it would not exceed a threshold of 25% ownership in the oil and gas firm. In October, the company had adopted the shareholders rights plan after Slim's Control...
Copyright 2023-2026 - www.financetom.com All Rights Reserved